Magellan Health (Magellan) recently announced the launch of reSET therapy, the first ever U.S. Food and Drug Administration (FDA) approved prescription digital therapeutic. The evidence-based, non-drug treatment seeks to improve outcomes for consumers battling addiction disorder.
As part of the pilot program, 250 patients will receive therapy through reSET therapy for a 12-week span. During that time, program retention will be tracked through increased engagement and therapy adherence. Magellan will also monitor the operational, economic, and clinical results of the program, which is currently in its pilot stage. During clinical studies, reSET has shown to increase drug abstinence, as well as increase patient retention in outpatient treatment.
Magellan Health, Inc. engages in the health care management business in the United States. The company’s health care segment engages in the management of behavioral health care services and employee assistance program services.
This was reported by Hit Consultant on January 17, 2018.
Contact Information: Magellan Health, Inc., 4800 Scottsdale Road Suite 4400, Scottsdale, Arizona 85251: (602) 572-6050; Website: www.magellanhealth.com